GRP78 regulates sensitivity of human colorectal cancer cells to DNA targeting agents. 2016

Nizar M Mhaidat, and Karem H Alzoubi, and Omar F Khabour, and Mohammed N Banihani, and Qosay A Al-Balas, and Sulaiman Swaidan
Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan. nizarm@just.edu.jo.

This study was carried out to investigate the activation status of unfolded protein response (UPR) in colorectal cancer (CRC) and its contribution to CRC resistance to chemotherapy-induced apoptosis. Chemotherapy-induced apoptosis was assessed by the propidium iodide method. Activation of UPR was evaluated in CRC cell lines using immunoblotting technique and in CRC tissues using immunohistochemistry. Findings of the present study revealed that the UPR is constitutively activated in CRC cell lines and CRC tissues isolated from patients, as evidenced by relatively high levels of the 78-kDa glucose-regulated protein (GRP78) and spliced X-box-binding protein 1 mRNA in tissue samples. In addition, CRC cell lines differentially responded to clinically relevant DNA-targeting agents including cisplatin, and 5-flourouracil. Moreover, the levels of GRP78 were inversely associated with sensitivity of CRC cells to chemotherapy-induced apoptosis. Inhibition of GRP78 by siRNA resulted in increased sensitivity of CRC cells to chemotherapeutic agents. Collectively, current results appear to provide novel insights into the role of UPR in determining sensitivity of CRC cells to chemotherapeutic agents and might have important implications for personalized CRC treatment.

UI MeSH Term Description Entries

Related Publications

Nizar M Mhaidat, and Karem H Alzoubi, and Omar F Khabour, and Mohammed N Banihani, and Qosay A Al-Balas, and Sulaiman Swaidan
April 1999, Biochemical and biophysical research communications,
Nizar M Mhaidat, and Karem H Alzoubi, and Omar F Khabour, and Mohammed N Banihani, and Qosay A Al-Balas, and Sulaiman Swaidan
July 2019, Bioscience reports,
Nizar M Mhaidat, and Karem H Alzoubi, and Omar F Khabour, and Mohammed N Banihani, and Qosay A Al-Balas, and Sulaiman Swaidan
February 2013, Biochemical and biophysical research communications,
Nizar M Mhaidat, and Karem H Alzoubi, and Omar F Khabour, and Mohammed N Banihani, and Qosay A Al-Balas, and Sulaiman Swaidan
December 2018, Oncology research,
Nizar M Mhaidat, and Karem H Alzoubi, and Omar F Khabour, and Mohammed N Banihani, and Qosay A Al-Balas, and Sulaiman Swaidan
January 2018, Neoplasma,
Nizar M Mhaidat, and Karem H Alzoubi, and Omar F Khabour, and Mohammed N Banihani, and Qosay A Al-Balas, and Sulaiman Swaidan
March 2016, Cancer chemotherapy and pharmacology,
Nizar M Mhaidat, and Karem H Alzoubi, and Omar F Khabour, and Mohammed N Banihani, and Qosay A Al-Balas, and Sulaiman Swaidan
December 2013, Biochimica et biophysica acta,
Nizar M Mhaidat, and Karem H Alzoubi, and Omar F Khabour, and Mohammed N Banihani, and Qosay A Al-Balas, and Sulaiman Swaidan
July 2016, Molecular medicine reports,
Nizar M Mhaidat, and Karem H Alzoubi, and Omar F Khabour, and Mohammed N Banihani, and Qosay A Al-Balas, and Sulaiman Swaidan
February 2016, Acta biochimica et biophysica Sinica,
Nizar M Mhaidat, and Karem H Alzoubi, and Omar F Khabour, and Mohammed N Banihani, and Qosay A Al-Balas, and Sulaiman Swaidan
June 2018, Oncology letters,
Copied contents to your clipboard!